{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-07-25-006",
    "source_story_id": "tmp-story-bladder-cancer-phase-three",
    "edition_id": "mp-2026-07-25-morning-0016",
    "edition_url": "https://themachinepress.com/edition/2026-07-25",
    "position": 6,
    "story_type": "dispatch",
    "section": "research",
    "editorial_classification": "editorial",
    "headline": "A Perioperative Pair Outruns Cisplatin",
    "slug": "a-perioperative-pair-outruns-cisplatin",
    "dek": "A phase 3 trial found better event-free survival with enfortumab vedotin plus pembrolizumab around bladder-cancer surgery.",
    "summary": "A phase 3 trial found better event-free survival with enfortumab vedotin plus pembrolizumab around bladder-cancer surgery.",
    "body_text": "In a phase 3 study of 808 people with muscle-invasive bladder cancer at 158 sites, perioperative enfortumab vedotin plus pembrolizumab reduced the risk of progression, recurrence, or death by 47% compared with cisplatin-based chemotherapy. At two years, roughly 80% of patients in the combination group and 66% in the chemotherapy group were event-free. Serious side effects were more frequent with the new regimen, so the survival result does not erase treatment tradeoffs.",
    "why_it_matters": "A phase 3 trial found better event-free survival with enfortumab vedotin plus pembrolizumab around bladder-cancer surgery.",
    "limitations": [
      "Serious side effects were more frequent with the new regimen, so the survival result does not erase treatment tradeoffs."
    ],
    "importance": 9,
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-25-006/a-perioperative-pair-outruns-cisplatin",
    "json_url": "https://themachinepress.com/story/mp-2026-07-25-006.json",
    "first_published_at": "2026-07-25T09:00:00.000-04:00",
    "modified_at": "2026-07-25T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-07-25-006-001",
        "text": "A phase 3 trial found better event-free survival with enfortumab vedotin plus pembrolizumab around bladder-cancer surgery.",
        "source_ids": [
          "source-2026-07-25-006"
        ],
        "qualification": "Serious side effects were more frequent with the new regimen, so the survival result does not erase treatment tradeoffs."
      }
    ],
    "source_ids": [
      "source-2026-07-25-006"
    ],
    "tags": [
      "bladder cancer",
      "phase 3 trial",
      "immunotherapy"
    ],
    "image_url": null,
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-07-25-006",
      "title": "Newswise: Phase 3 bladder-cancer trial",
      "publisher": "Newswise",
      "url": "https://www.newswise.com/articles/new-treatment-approach-improves-survival-and-reduces-recurrence-risk-for-patients-with-muscle-invasive-bladder-cancer",
      "canonical_url": "https://www.newswise.com/articles/new-treatment-approach-improves-survival-and-reduces-recurrence-risk-for-patients-with-muscle-invasive-bladder-cancer",
      "source_type": "secondary_reporting",
      "is_primary_source": false,
      "published_at": null,
      "accessed_at": "2026-07-25T08:26:47.000-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-07-25-006-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "A Perioperative Pair Outruns Cisplatin",
    "publisher": "The Machine Press",
    "published_at": "2026-07-25T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-25-006/a-perioperative-pair-outruns-cisplatin"
  }
}